Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christopher D.M. Fletcher, M.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Christopher Fletcher and Chandrajit Raut.
Connection Strength

0.799
  1. High rates of histopathologic discordance in sarcoma with implications for clinical care. J Clin Oncol. 2011 May 20; 29(15_suppl):10065.
    View in: PubMed
    Score: 0.121
  2. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15.
    View in: PubMed
    Score: 0.109
  3. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24.
    View in: PubMed
    Score: 0.107
  4. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol. 2008 Dec; 32(12):1896-904.
    View in: PubMed
    Score: 0.102
  5. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31.
    View in: PubMed
    Score: 0.086
  6. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 Aug 15; 127(16):2934-2942.
    View in: PubMed
    Score: 0.060
  7. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):425-435.
    View in: PubMed
    Score: 0.052
  8. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):375-383.
    View in: PubMed
    Score: 0.045
  9. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
    View in: PubMed
    Score: 0.037
  10. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
    View in: PubMed
    Score: 0.031
  11. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008 Nov; 44(16):2404-10.
    View in: PubMed
    Score: 0.025
  12. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.